Joseph Mikhael, MD, MEd, highlights the clinical and logistical advantages of the novel on-body injector developed for the ...
Dr. Monty Pal discusses how the increasing use of adjuvant immunotherapy has introduced new considerations for the management ...
Joseph Mikhael, MD, MEd, describes the impact of the FDA's approval of subcutaneous isatuximab with an on-body injector device. Joseph Mikhael, MD, MEd, professor in the Applied Cancer Research and ...
CMS would set 340B drug payment at ASP–33.4%, lowering Medicare and beneficiary drug outlays while redistributing equivalent ...
KOMET-007 shows ziftomenib plus venetoclax/azacitidine drives deep MRD-negative remissions in R/R AML, with manageable ...
Bispecific antibodies have emerged as a transformative class of therapies in multiple myeloma and beyond, but the need for ...
Hansen, MD, discusses outcomes from a large retrospective study of patients treated with ciltacabtagene autoleucel for ...
The first clinical case presents a 58-year-old female never-smoker with persistent cough, mild dyspnea, and new right-sided ...
The panel discusses the full multidisciplinary team required to optimize outcomes for patients with ROS1-positive advanced ...
Dr. Monty Pal summarizes his practical first-line treatment algorithm for advanced renal cell carcinoma (RCC), highlighting ...
A third CRL was issued for rivoceranib plus camrelizumab in first-line unresectable/metastatic HCC, driven by cGMP ...
Pettit, MD, and participants discussed second-line considerations in high-risk polycythemia after hydroxyurea failure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results